Proprietary drug delivery system
TesoRx has developed a novel drug delivery system ("DDS") that enhances and reformulates proven drugs into more effective treatments. Its proliposomal technology overcomes formulation challenges of drugs that are poorly water-soluble, have low membrane permeability, high metabolism or systemic toxicity. DDS is highly modifiable and has been successfully applied to solid and liquid therapies.
The underlying technology was created by TesoRx co-founder, Dr. Guru Betageri, and exclusively licensed from Western University of Health Sciences in Pomona, California ("WUHS"). Ongoing application of DDS for new drug candidates takes place in TesoRx's comprehensive wet lab at the TesoRx Centre of Excellence next to the WUHS.
TesoRx has applied DDS for its own products and has made it available to pharmaceutical companies reformulating legacy products or developing new ones. The DDS licensing terms are available from the company.
Oral drug delivery - Testosterone Undecanoate (TSX-011)
The main challenge with oral delivery of Testosterone is the high first pass metabolism of the molecule in the gastrointestinal tract when delivered orally, that prevents systemic uptake of the hormone in the body. Testosterone is furthermore poorly water soluble and has proven to be an extremely difficult challenge as a safe and efficacious oral formulation.
Utilizing TesoRx's DDS, Testosterone Undecanoate is formulated as a solid proliposomal powder that is encased in an enteric coated capsule. The capsule bypasses gastric degradation in the stomach and the liposomal TU formulation is absorbed into the GI lymphatic system, thus, solving the first pass metabolism challenge (1).
Alkaline pH levels in the intestine cause the capsule to degrade, releasing proliposomal powder that spontaneously hydrates and forms micelles and liposome complexes for lymphatic absorption (2). By bypassing the liver, the DDS has solved the challenge of hepatic metabolism and allows for excellent oral bio-availability of the drug.
Intravesical chemotherapy delivery example - Proliposomal Intravesical Paclitaxel ("PLIP")
Current intravesical treatments for bladder cancer have solubility, intravesical persistence and absorption challenges in the hostile acidic environment within the bladder. TesoRx's pro-liposomal platform technology allows proven oncology agents to be targeted directly at tumors and reducing the risk of systemic toxicity.
Highly lipophilic paclitaxel is incorporated as a proliposomal formulation that can be easily stored in a closed, ready for use system.
Before intravesical administration, the powder is reconstituted within a closed packaging system with no risk of contamination to the health care professional. It spontaneously creates soluble liposome complexes in the acidic bladder environment thereby solving the solubility challenge of these treatments.
Read more about how this technology is applied to TesoRx's Bladder Cancer product.